Head to head
Semaglutide against Bimagrumab
The muscle question, asked directly. Weight loss on a GLP-1 includes lean mass, and bimagrumab was designed to move fat and muscle in opposite directions. Unusually, the two were randomised against each other and against their combination in the same trial.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Column B
BimagrumabBimagrumab (anti-activin receptor antibody)
A muscle-preserving antibody that blocks activin receptors to reduce fat while increasing lean mass, being studied alongside GLP-1 drugs.
These two were tested against each other directly
A head to head trial, not two separate records compared by us.
Least squares mean weight change at week 48 was 9.3 kg lower on bimagrumab 30 mg per kg, 14.2 kg lower on semaglutide 2.4 mg and 17.8 kg lower on the high dose combination, against 3.3 kg on placebo, all p < 0.001 against placebo. Bimagrumab's common adverse events were muscle spasms, diarrhoea and acne; semaglutide's were nausea, diarrhoea, constipation and fatigue.
What the trial was
Double-blind, placebo-controlled phase 2 trial. 507 adults with obesity, defined as BMI 30 or more, or 27 or more with at least one obesity-associated complication, excluding diabetes, randomised equally to nine groups for 48 weeks: placebo, bimagrumab 10 or 30 mg per kg intravenously every 12 weeks, semaglutide 1.0 or 2.4 mg weekly, and the combinations. An open-label extension ran to week 72. Primary endpoint was absolute change in body weight at week 48.
What the authors concluded
The authors conclude that bimagrumab plus semaglutide produced substantial reductions in body weight, with safety consistent with the known profiles of both drugs.
Where this result is weak
The published comparisons are each arm against placebo, not bimagrumab against semaglutide, so reading the two numbers as a ranking goes beyond what the trial tested. It is a phase 2 of 507 people over 48 weeks with total body weight as the endpoint, which is exactly the endpoint that does not capture bimagrumab's stated purpose, since a drug that adds muscle while removing fat is penalised on the scale. Sponsored by Eli Lilly, with most authors employed by or holding equity in Lilly or Versanis.
Side by side, on the facts we can check
| Attribute | Semaglutide | Bimagrumab |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | Investigational for obesity / body composition; Phase 2 BELIEVE published 2026 |
| Half-life | ~7 days | Weeks (antibody) |
| Molecular weight | 4,113.6 Da | About 150 kDa (IgG1 monoclonal antibody; KEGG lists the full heavy and light chain sequences but no mass) |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Blocks activin type II receptors, neutralizing myostatin and activin signaling to build muscle and reduce fat mass. |
| Human studies cited | 5 | 2 |
| Legal status, US | FDA-approved, prescription only | Investigational, not approved |
Frequently asked questions
What is the difference between Semaglutide and Bimagrumab?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. Bimagrumab: A muscle-preserving antibody that blocks activin receptors to reduce fat while increasing lean mass, being studied alongside GLP-1 drugs.
Which has stronger research evidence, Semaglutide or Bimagrumab?
This database does not grade compounds. It counts what was run in people: 5 of the 5 studies cited on the Semaglutide profile were human work, against 2 of 2 for Bimagrumab. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Semaglutide and Bimagrumab FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Bimagrumab: Investigational for obesity / body composition; Phase 2 BELIEVE published 2026.
Related posts
Blog articles that cover Semaglutide or Bimagrumab, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.